The tinnitus research literature suggests that N-methyl-D-aspartate (NMDA) receptor antagonists may be useful in reducing tinnitus. Nitrous oxide, a member of the NMDA receptor antagonist class, is a widely used general anesthetic and sedative with a proven safety record.
S ubjective, idiopathic, nonpulsatile tinnitus ("tinnitus") is the perception of sound in the absence of an external acoustic stimulus. Approximately 50 million Americans experience chronic tinnitus; of these, 10 million have bothersome tinnitus. 1 Bothersome tinnitus is associated with poorer working memory, slower cognitive processing speeds and reaction times, and deficiencies in selective attention. 2 To date, effective treatment for tinnitus is limited to cognitive behavior therapy. 3, 4 Hearing aids may provide benefit for those patients with tinnitus and hearing loss. 5 Sound therapy, or masking, may be of limited benefit. 6 Pharmacologic therapy, including antidepressants, 7 anxiolytics, 8, 9 and anticonvulsants, 10 are of limited benefit, have significant adverse effects, and are not suitable for long-term use. Dietary supplements, 11, 12 acupuncture, 13 and transcranial magnetic stimulation 14 are also not recommended for tinnitus. The identification of an effective and fast-acting intervention would be a significant advantage for the patient with tinnitus. Nitrous oxide is an N-methyl-D-aspartate (NMDA) receptor antagonist, a class of drugs shown to have antidepressant effects. 6 A previous trial examined the effect of nitrous oxide for treatment-resistant major depressive disorder. 15 In that masked, placebo-controlled crossover trial, 20 patients with treatmentresistant depression were randomly assigned to receive 1 hour of 50% nitrous oxide or 50% oxygen (control), followed 1 week later by the other treatment. Depressive symptoms significantly improved at 2 hours and 24 hours after nitrous oxide compared with control. The proof-of-concept trial demonstrated that nitrous oxide had a rapid antidepressant effect. The NMDA receptors are maintained at synapses throughout the auditory pathway, including in the cochlea, dorsal cochlear nucleus, and higher brainstem structures, and have diverse roles in synaptic development, plasticity, and processing of temporal auditory information. Generally, the NMDA receptors promote excitation at synapses throughout the auditory pathway and have diverse roles in synaptic development and auditory information processing. In the setting of chronic damage to the auditory system, overactivation of the NMDA receptors leads to aberrant spontaneous neuronal firing in the cochlea and auditory brainstem structures, which can further perpetuate damage and disease in a feedforward mechanism. [16] [17] [18] [19] [20] Studies by Guitton and Dudai 18 and by Puel 19 showed that the administration of the NMDA receptor antagonists before the administration of salicylate was effective in preventing acute excitotoxic tinnitus, establishing that salicylate induces tinnitus through its action on the NMDA receptors. Therefore, the NMDA receptors are thought to be implicated in the generation and perpetuation of several auditory diseases, including tinnitus. [19] [20] [21] We hypothesized that the administration of nitrous oxide may provide a rapid reduction in subjective, bothersome tinnitus.
Methods

Study Design and Oversight
This randomized, placebo-controlled crossover trial was approved by the institutional review board at Washington University School of Medicine in St Louis. Each participant attended 2 intervention sessions, one "placebo" and one "treatment." The 2 intervention sessions were held at least 14 days apart to allow for adequate washout of any treatment effect. 15 Participants were followed up through completion of the second arm of the study. Participants enrolled in the study were randomly assigned to receive either placebo that was followed by nitrous oxide or nitrous oxide that was followed by placebo according to a computer-generated randomization sequence. Only the statistician (D.K.) and the anesthesiology team (B.Y. and P.N.) directly involved in the administration of the placebo and nitrous oxide had access to the group assignments. All participants and other study team members (H.Y.H., O.K., and F.T.B.) administering survey assessments remained masked. The intervention sessions were indistinguishable in setting, setup, and monitoring to maintain masking for the participants and study team members. All intervention sessions were performed at the Washington University Clinical Research Unit, a component of the Center for Applied Research Sciences. The full trial protocol can be accessed in Supplement 1.
Participants
Forty participants were recruited from 2 clinical research databases, the Washington University Volunteers for Health Research Participant Registry and the Otolaryngology Research Participant Registry. Eligibility criteria included adults aged 18 to 65 years who had subjective, idiopathic, nonpulsatile bothersome tinnitus of 6 months' duration or longer and were able to communicate in English and provide written informed consent. Individuals were included only if they self-reported to be "Bothered more than a little but not a lot" or more on a 5-point Global Bothersome Scale (GBS), which ranges from "Not bothered" to "Extremely bothered." Individuals were excluded if they had a history of bipolar disorder, schizophrenia, or schizoaffective disorder at any time in their life or if they had substance abuse or dependence within the last year. Individuals were also excluded if they demonstrated any of the following: (1) active psychotic symptoms; (2) significant pulmonary disease and/or requirement of supplemental oxygen; (3) contraindication against the use of nitrous oxide, including
Key Points
Question Can the administration of nitrous oxide reduce or eliminate bothersome tinnitus?
Findings In this randomized clinical trial of 40 participants, the Tinnitus Functional Index after intervention was lower than before intervention in the placebo arm and in the nitrous oxide arm. The within-participant mean difference in the change in the Tinnitus Functional Index of the placebo arm compared with the nitrous oxide arm was −1.1 points, which was neither clinically or statistically significant.
Meaning Nitrous oxide is no more effective than placebo for the treatment of tinnitus.
pneumothorax, bowel obstruction, middle ear occlusion, elevated intracranial pressure, chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B 12 , pregnancy, or breastfeeding; (4) previous NMDA receptor antagonist treatment (eg, ketamine hydrochloride) within the last 3 months; (5) tinnitus related to cochlear implantation, retrocochlear lesion, Meniere disease, or other known anatomic lesions of the ear or temporal bone; or (6) tinnitus related to any active litigation-related event.
Intervention
Patients attending the placebo session were administered an inhalation of 50% nitrogen and 50% oxygen for 40 minutes, and those attending the active treatment session were administered an inhalation of 50% nitrous oxide and 50% oxygen for 40 minutes. The selection of the 50% nitrous oxide concentration was based on the use in the previous trial for treatment-resistant major depressive disorder. 15 Each mixture of gases was administered via a nitrous oxide delivery apparatus approved by the US Food and Drug Administration (FDA). The total gas flow was set at 4 to 6 L/min. Participants were monitored during and after each intervention session according to the American Society of Anesthesiologists standard, 22 including continuous 3-lead electrocardiogram, pulse oximetry, and noninvasive blood pressure under the supervision of an anesthesiologist. After the 40-minute intervention, all participants were observed for an additional hour and were then assessed by a study team member for safe discharge. Masking of participants was assessed by asking each participant at the end of the first intervention session to give their best guess as to which intervention (placebo or nitrous oxide) they had just received.
Outcome Measures
The primary outcome measure was the change in the Tinnitus Functional Index (TFI) 1 week after intervention compared with before intervention. The TFI is a 25-question survey assessing tinnitus effect on quality of life. Participants were asked to rate on a scale from 0 (low) to 10 (high) the degree of unpleasantness, cognitive interference, sleep disturbance, auditory difficulties, interference with relaxation, and emotional distress associated with their tinnitus. Subindexes were summed and scaled to an index of 0 to 100. An index less than 25 indicates mild problems due to tinnitus and little need for intervention, while an index between 25 and 50 indicates significant problems due to tinnitus, with possible need for intervention. Secondary outcome measures included the Patients' Global Impression of Change (PGIC) score and the change in the GBS score. The GBS measured participants' self-assessment of bothersome tinnitus on the 5-point scale ranging from "Not bothered" to "Extremely bothered." On the PGIC, participants reported their perception of change due to intervention, if any, with regard to activity limitations, symptoms, emotions, and overall quality of life related to tinnitus. Participants chose from 7 options ranging from "No change or worsened" to "Great deal better, considerable improvement." The preintervention TFI and GBS data were collected immediately before the participant received the intervention, and the postintervention TFI and GBS data were collected 1 week after each intervention. Participants completed the PGIC 1 week after each intervention. All data were collected using research electronic data capture (REDCap).
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Statistical Analysis
The main outcome variable was the change in the TFI from before to after intervention. The effect size was determined a priori based on the clinically meaningful change of 13 points as defined by Meikle et al 24 (the authors of the TFI), assuming the same variability in the TFI change shown in previous tinnitus studies. 25, 26 We estimated that a sample size of 32 participants would provide us with 81% power to detect an effect size of 0.52 or larger at 2-sided α = .05. Assuming a 20% dropout rate, we planned to enroll 40 participants with tinnitus in this study. Standard descriptive statistics were used to describe the sample of participants included in the study. Bivariate analysis was performed to compare the distribution of characteristics between participants randomized to receive placebo first and those randomized to receive nitrous oxide first. Given the crossover study design, carryover effect was assessed by comparing the TFI at the start of the first session with the TFI at the start of the second session for the total cohort, the group receiving placebo first, and the group receiving nitrous oxide first.
The change in the TFI from before to after intervention was calculated for each participant and each intervention. The mean change in the TFI was determined for each intervention, and the mean within-participant difference between the placebo and nitrous oxide intervention groups was determined. A repeated-measures mixed linear model using the Kenward-Roger option 27 to adjust df for small sample sizes and with participant as a random effect was used to investigate the change in the TFI before and after intervention and to test whether this change between the 2 interventions was significantly different. Participants who experienced a reduction in the TFI of 13 or more points were defined as intervention responders. The number of responders was calculated for each intervention arm and compared between the 2 interventions. Effectiveness of masking was assessed by calculating the percentage of participants who correctly identified which intervention they received during their first session.
Results
Participants
Recruitment of participants and implementation of the trial were conducted between October 15, 2016, and June 22, 2017. A total of 71 individuals were screened for participation in the study. Of these, 24 did not pass screening and were ineligible for participation in the study, and 7 passed screening but chose not to participate. The remaining 40 were enrolled and were evenly randomized into the groups of placebo first or nitrous oxide first. Of those enrolled, 3 participants either withdrew or were lost to follow-up after completion of the first intervention session. Thirty-seven participants completed the entirety of the study, including the intervention sessions and all assessments ( Figure 1 ). The mean (SD) age of the study population was 52.9 (11.1) years. There were equal numbers of male participants (n = 20) and female participants (n = 20). Participants had been experiencing tinnitus for a median duration of 13 years (range, 1-56 years). The median Patient Health Questionnaire 19 score was 3 (range, 0-27; the higher the score, the higher the severity of depression: 0-4, none; 5-9, mild; 10-14, moderate; 15-19 moderately severe; and 20-27, severe). The median TFI at baseline was 41 (range, 6-92). On the GBS, 24 participants (60%) reported being "Bothered more than a little but not a lot," 12 participants (30%) reported being "Bothered a lot," and 4 participants (10%) reported being "Extremely bothered." Baseline demographic characteristics, the TFI, and the GBS score are listed in the Table; tinnitus characteristics are listed in the eTable in Supplement 2. There were no significant differences between the group of participants randomized to receive placebo first and the group of participants randomized to receive nitrous oxide first.
Main Outcome Variable
There was no significant difference in the TFI at the beginning of the second session compared with the beginning of the first session for the total cohort independent of the order of interventions (mean difference, 1.2 points; 95% CI, −4.5 to 2.1 points), nor was there a significant difference between the group receiving placebo first (mean difference, −2.9 points; 95% CI, −8.5 to 2.7 points) and the group receiving nitrous oxide first (mean difference, 0.5 points; 95% CI, −3.6 to 4.6 points). The TFI after intervention was a mean (SD) of 1.8 (8.8) points lower than before intervention in the placebo arm and a mean (SD) of 2.5 (11.0) points lower than before intervention in the nitrous oxide arm ( Figure 2) . Mixed model analysis revealed that the change in the TFI from before to after intervention did not differ between the groups. The within-participant mean difference in the change in the TFI among participants receiving placebo compared with nitrous oxide was −1.1 points (95% CI, −5.6 to 3.4 points). The effect size of −1.1 points and even the upper bound of the 95% CI were less than the desired clinically significant change of a 13-point reduction in the TFI. Four participants in the placebo arm and 5 participants in the nitrous oxide arm achieved a reduction in the TFI of 13 points or greater.
Secondary Outcome Variables
The PGIC response was recorded for each participant 1 week after each session. Comparing the placebo and nitrous oxide arms, similar numbers of participants reported the change in their tinnitus as "No change or worsened" (24 in the placebo arm and 20 in the nitrous oxide arm) at one extreme and as "Better, definite improvement" (1 in the placebo arm and 1 in the nitrous oxide arm) at the other extreme. No participants reported the highest level of change ("Great deal better, considerable improvement"). A summary of the PGIC responses is shown in Figure 3 . Most participants did not have any change in the GBS score after intervention compared with before intervention in both the placebo arm (28 participants) and the nitrous oxide arm (34 participants). Within each arm, the remaining responses were almost evenly split between an increase in score indicating worsening of bothersome tinnitus by 1 point (5 in the placebo arm and 2 in the nitrous oxide arm) and a decrease in score indicating improvement of bothersome tinnitus by 1 point (5 in the placebo arm and 2 in the nitrous oxide arm). In addition, 1 participant in the placebo arm experienced an increase of 2 points in the GBS score.
Of the 20 participants who were assigned to the group receiving placebo first, 17 correctly guessed they had received placebo during the first session. Similarly, of the 20 participants who were assigned to the group receiving nitrous oxide first, 18 participants correctly guessed they had received nitrous oxide treatment during the first session. Overall, 88% (35 of 40) of participants guessed correctly, which is significantly higher than what we would expect by chance alone if the masking was effective.
Safety
In total, 3 adverse events occurred in 3 different participants. All adverse events were temporary and fully resolved. The 3 adverse events were nausea, light-headedness, and panic attack, and all occurred during the administration of nitrous oxide. No serious adverse events were reported. 
Discussion
In this intent-to-treat randomized clinical trial, we demonstrated that nitrous oxide is no more effective than placebo for the treatment of tinnitus. Because of the crossover study design, each participant received both placebo and nitrous oxide at different points during the study, allowing participants to serve as their own controls. In both the placebo and nitrous oxide arms, the observed effects on tinnitus and bothersome tinnitus can be interpreted as small as measured by the change in the TFI from before to after intervention. The change in the TFI was not statistically significantly different between the 2 intervention arms, and the upper bound of the 95% CI did not exceed the value needed to indicate a clinically meaningful effect. Masking of participants was assessed by determining whether the percentage of participants who correctly guessed the intervention they had received was significantly greater than 50%. In this study, a large percentage of participants were able to identify the intervention. Although extensive measures were taken to preserve masking for the study team members administering surveys, masking was not achieved for most participants. Nitrous oxide is a colorless and odorless anesthetic that serves as a sedative at lower doses, as used in this study. It is likely that the dissociative effects of nitrous oxide itself were recognizable to participants even at routinely used doses. Despite ineffective masking, there was no effect of the nitrous ox- ide intervention on the results of the study, which strengthens the validity of the findings as a true negative finding. Furthermore, the fact that an identical dose of nitrous oxide has rapid antidepressant effects in patients with treatment-resistant major depression, 15 but not in tinnitus as found herein, suggests that the underlying neurobiology between depression and tinnitus is different.
Another consideration applicable to any study assessing tinnitus is the fact that directing attention to a patient's tinnitus in the absence of an evidence-based approach, such as cognitive behavior therapy, may in fact increase his or her perception of tinnitus severity or bother. 28 Counter to this effect, the placebo effect in tinnitus investigations has been documented to be as large as 40% of patients reporting a change in tinnitus. 29 The placebo effect was small in this study, which may be explained by the inadequate participant masking. Despite its prevalence, tinnitus and its pathophysiologic causes are still not well understood. The NMDA receptors are maintained at synapses throughout the auditory pathway, including in the cochlea, dorsal cochlear nucleus, and higher brainstem structures, and have diverse roles in synaptic development, plasticity, and processing of temporal auditory information. 20, 30 While the NMDA receptors are likely implicated in both the generation and perpetuation of tinnitus, as well as in models of auditory plasticity, they do not represent the entire picture. Guitton and Dudai 18 induced tinnitus via acute noise insult in a rat model; subsequently, at varying time points after insult, they administered an NMDA receptor antagonist, ifenprodil, to abate the development of tinnitus induced by long-term noise. At 2 weeks after insult, they assessed whether tinnitus had developed. They concluded that tinnitus undergoes a consolidation period of several days, meaning there is a particular time window during which tinnitus could be avoided through the use of the NMDA receptor antagonists acting on cochlear receptors. No animals in the study arm that received ifenprodil in the first 4 days after insult developed tinnitus; in contrast, a significant proportion of animals in the study arm that received ifenprodil 8 days after exposure developed tinnitus. Furthermore, the authors make a comparison between tinnitus and memory insofar as the 2 processes share the property of consolidation, characterized as a time window of susceptibility to blockers of experience-dependent plasticity. Therefore, it is conceivable that application of the NMDA receptor antagonists, such as nitrous oxide, is more effective in an immediate postexposure setting in response to noise insult or high doses of salicylates.
Bothersome tinnitus is a medical condition with the potential to be debilitating. Coupled with the fact that to date the FDA has not approved any pharmacologic treatments for tinnitus and other treatment options are limited, we see that a substantial tinnitus problem exists for 50 million people in the United States, or 15% of the population. This study serves as another call in highlighting the need for further research into 
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Effect of Nitrous Oxide as a Treatment for Subjective, Idiopathic, Nonpulsatile Bothersome Tinnitus both the pathophysiologic causes of tinnitus and the development of effective treatment.
Limitations
The limitations of the study include a small sample size that prevented exploration of differential treatment effects in unique clinical subgroups. In addition, a large number of participants were likely unmasked to treatment assignment, and this could have affected their assessment of treatment outcome. We believe that unmasking only served to strengthen the negative findings of the study.
Conclusions
Our randomized clinical trial demonstrated that nitrous oxide, a member of the NMDA receptor antagonist class, was no more effective than placebo for the treatment of subjective, idiopathic, nonpulsatile tinnitus. To date, no FDA-approved pharmacologic treatments exist for tinnitus, which remains a prevalent and debilitating condition. Further efforts are needed to understand the pathology involved in long-standing tinnitus and to develop effective pharmaceutical agents.
18. Guitton 
Study Drug
Nitrous oxide (laughing gas). This is an FDA-approved general anesthetic and sedative agent used in hospitals and dentist offices. The use of nitrous oxide to treat tinnitus is off-label and outside of the approved indication. Nitrous oxide will be administered under supervision of an attending-level anesthesiologist and using standard anesthesia equipment (mobile anesthesia machine, standard periprocedural monitoring, oxygen, rescue equipment).
Study Design
Prospective, randomized, double-blinded, placebo-controlled cross-over trial. Subjects will first receive either up to 50% nitrous oxide/50% oxygen or "placebo" (50% nitrogen [inert]/50% oxygen) in a 40-minute single session. In the subsequent session, subjects will receive the other treatment intervention. The two sessions will be held 2 weeks apart and will be indistinguishable from each other in setting, setup, and monitoring.
Inclusion and Exclusion Criteria
Inclusion Criteria a) Adult men and women 18-65 years of age b) Subjective, unilateral or bilateral, non-pulsatile tinnitus for at least 6 months duration c) Either "Bothered more than a little but not a lot", "Bothered a lot", or "Extremely bothered" on the Global Bothersome scale d) Able to give informed consent e) Must be able to read, write, and understand English pending. l) Any medical condition, which, in the opinion of the PI, confounds study results or places the subject at greater risk
Primary Outcome and Measurements
The difference in the difference in patient-reported tinnitus symptoms according to Tinnitus Functional Index (TFI) between baseline and 1 week after each intervention. Secondary outcome measure will be the same calculation performed for the Momentary Assessment of Tinnitus (MAT) questionnaire.
ABSTRACT
Tinnitus, the perception of sound in the absence of external acoustic stimulation, is a common yet poorly understood disease that currently lacks effective front-line treatment. Many therapies focus on mitigating the effects of tinnitus on patients' quality of life, such as through habituation or masking with white noise. However, the tinnitus research literature suggests that NMDA receptor antagonists may prove to be useful in reducing tinnitus itself. [6, 9, 11, 12] Nitrous oxide belongs to the class of NMDA receptor antagonists, and additionally is widely-used, noninvasive, and has a proven safety profile. As such, nitrous oxide may be the drug of choice for testing the efficacy of NMDA receptor antagonists on reducing subjective, bothersome tinnitus.
We propose conducting a pilot randomized placebo-controlled, double-blind crossover study in which patients attend two sessions where they receive either 50% nitrous oxide in oxygen or 50% nitrogen, 50% oxygen for a period of 40 minutes. Tinnitus will be assessed using the Tinnitus Functional Index (TFI) upon enrollment, then reassessed 1 week following each intervention session. Secondarily, the Momentary Assessment of Tinnitus (MAT) questionnaire will be administered at baseline before intervention, 1 hour after intervention, 1 day after intervention, and 1 week after intervention.
SPECIFIC AIMS
Aim 1.
To evaluate the efficacy of nitrous oxide as treatment for tinnitus
BACKGROUND
Subjective, idiopathic, non-pulsatile tinnitus ("tinnitus") is perception of sound without the presence of an external acoustic stimulus. Approximately, 60 million Americans experience chronic tinnitus and 15 million of these people have bothersome tinnitus. Research at Washington University (WU) [1] and elsewhere showed that bothersome tinnitus is associated with poorer working memory, slower processing speeds and reaction times, and deficiencies in selective attention. These findings indicate that tinnitus interferes with attention and other important non-auditory cortical networks and the effects may be mediated by stress and its effects on the central nervous system.
Currently, no effective front-line therapy exists for tinnitus. Many patients use external sound therapy such as white noise generators to mask the perceived sound, or counseling therapy to habituate the patient to the perceived sound. While these treatments often help decrease the effects tinnitus has on quality of life, they do not alleviate the tinnitus itself. Surgical treatment such as nerve transection remains controversial. [2, 3] Currently, there are no FDA-approved drugs specifically for tinnitus. [4, 5, 6] However, there are antidepressant and antianxiety medications such as desipramine (Norpramin), alprazolam (Xanax), or lorazepam (Ativan) prescribed to patients with tinnitus. [6, 7] According to the American Tinnitus Association, these psychotropic drugs can reduce the psychological burden of tinnitus for some patients, but again do not reduce perception of tinnitus itself. Furthermore, side effects of the drugs include nausea, blurred vision, and insomnia, and they can be habit-forming. As such, the side effects often interfere with patients' ability to concentrate and with other cognitive functions. [7] A previous trial performed by Dr. Peter Nagele at WU examined using nitrous oxide as a treatment for major depressive disorder (MDD). Results showed significant and rapid improvement of depressive symptoms. [8] Nitrous oxide is an N-methyl-D-aspartate (NMDA) receptor antagonist, a class of drugs that have shown to have antidepressant effects. [9] There is a general consensus in tinnitus research that subjective neural-generated tinnitus results from abnormal spontaneous activity somewhere in the auditory pathway, and the neural events that lead to tinnitus are themselves a result of altered activity in the cochlea. [10, 11] Cochlear NMDA receptors have been implicated in neural-generated tinnitus. [10, 12, 13] Acute excitotoxic tinnitus results from administration of salicylate, but prior administration of NMDA receptor blockers prevents salicylate-induced tinnitus. [12] Given this proposed mechanism of action, nitrous oxide, an NMDA receptor antagonist, presents a possible therapeutic strategy for treating tinnitus.
In this pilot study, we plan to assess the impact of nitrous oxide on tinnitus symptoms and degree of bother. For this pilot study, we will not exclude patients with depression, and thus we will not be able to assess whether the mechanism of nitrous oxide on reducing tinnitus is independent of the aforementioned mechanism in depression. Regardless, we believe nitrous oxide may be an effective treatment for tinnitus and believe a pilot study is indicated.
DRUG INFORMATION
Nitrous oxide (laughing gas) is a colorless, odorless gas. Nitrous oxide is the oldest and most widely used FDA-approved anesthetic gas. It is commonly used as a component of general anesthesia and as a sedative/analgesic agent used in hospitals and dentist offices. The onset as well as offset of effect is within a few minutes. Nitrous oxide is the least potent of inhalational anesthetics. Concentrations above 1atm are theoretically needed to produce complete general anesthesia when nitrous oxide is used as a sole agent. Therefore, concentrations typically used (50%) in dentistry and pediatrics achieve only mild to moderate sedation (but potent analgesia) and are not sufficient to produce general anesthesia. Well-known side effects include euphoria, sedation, nausea and vomiting, and inactivation of vitamin B12 (commensurate with the duration of exposure and concentration used). In general, exposure to 50% nitrous oxide for 40 minutes is considered extremely safe. The use of nitrous oxide to treat tinnitus is off-label and outside of the approved indication.
ELIGIBILITY
Inclusion Criteria a) Adult men and women 18-65 years of age b) Subjective, unilateral or bilateral, non pulsatile tinnitus for at least 6 months duration c) Either "Bothered more than a little but not a lot", "Bothered a lot", or "Extremely bothered" on the Global Bothersome scale d) Able to give informed consent e) Must be able to read, write, and understand English Potential participants will be screened according to inclusion and exclusion criteria over the telephone, and those who meet inclusion criteria will be invited to the 8th floor McMillan Building Clinical Research Outcomes Office to discuss study participation. The potential participant will have the opportunity to review the consent form and have questions about the study answered by the study team. The PI, or designee, will obtain written consent prior to the start of study related procedures.
We will enroll a total of 40 participants with bothersome tinnitus to achieve at least 30 evaluable participants. Participants will be offered $50 in remuneration for their time and effort in this study, to be given upon completion of study participation.
METHODS
Study Design
This is a prospective, randomized, double-blinded, placebo-controlled crossover trial where 40 patients will undergo two treatment sessions in randomized order. In one session, subjects will receive up to 50% nitrous oxide/50% oxygen for 40 minutes ("Treatment"). In the other session, subjects will receive up to 50% nitrogen [inert]/50% oxygen for 40 minutes ("Placebo"). The two sessions will be held 2 weeks apart and will be indistinguishable from each other in setting, setup, and monitoring.
No pre-enrollment laboratory assessments will be required. However, a health history will be taken at screening.
Randomization
Each participant will be randomly assigned to either the "Treatment first" or "Placebo first" group. The randomization scheme will use permuted blocks of randomly varying sizes generated by the study statistician using SAS statistical software and a password-protected Microsoft Excel spreadsheet will be used to create and store the study IDs and the randomization order. Each block will contain equal numbers of assignments to the treatment first and placebo first in randomized order. To account for the anticipated 20% dropout rate (i.e., as a result of withdrawal, being lost to follow-up, and so on), the randomization table will be generated for 50 subjects.
Blinding
Participants will be blinded to the randomization order. Nitrous oxide is a colorless and odorless gas, which makes it unlikely for participants to identify the group assignment. Likewise, the study setup will be identical for both sessions, which will make an inadvertent unblinding of the study unlikely. For the anesthesiology team responsible for the administration of the nitrous oxide treatment, the group assignment will be known. This team is completely separate from the team assessing the study outcomes, which will be blinded to the treatment received. Treatment administration and outcomes assessment will also be physically separated in different rooms within the Clinical Research Unit (CRU) to prevent unblinding. To assess the integrity of the blind, subjects will be asked immediately after each administration to guess which treatment -active or placebo they just received.
Setting
The study will be performed in the Clinical Research Unit (CRU) at the Center for Applied Research Sciences, located on the 4 th and 5 th floors of Barnard Hospital. The CRU is staffed by nurses, technicians, and medical assistants with experience in implementing clinical research studies, including specialized protocol-required procedures. The facility consists of 6 rooms and 12 semi-private beds, and is equipped with state-of-the art anesthesia machines, monitoring and anesthesia equipment, and resuscitation equipment and devices. The CRU has anesthesia equipment set up to allow for treatment of two participants at once. We will pay the CRU an annual fee of $500 for this active protocol.
Administration of Study Treatment
Except for the choice of gas (nitrous oxide or nitrogen [inert]; both mixed with 50% oxygen), treatment sessions will be identical. The gas mix will be administered via a standard anesthesia face mask through tubing connected to the inhalation apparatus. Inhaled and exhaled gas concentrations of nitrous oxide, oxygen and nitrogen will be monitored and adjusted according to protocol. Total gas flow will be 2-4 L/min.
Participants will be NPO (although liquids may be freely consumed) for 2 hours prior to each intervention session as a precaution for possible nausea. Participants will be monitored during and after the treatment according to American Society of Anesthesiologists (ASA) standard, which includes continuous 3-lead ECG, pulsoximetry, non-invasive blood pressure and end tidal CO2 under the supervision of an attending-level anesthesiologists. [15] After the 40 minute treatment session, participants will be monitored in the CRU for 1 hour. Participants will then be asked to complete the Momentary Assessment of Tinnitus (MAT) questionnaire before leaving. A study team physician will determine when the participant meets criteria for discharge as described by the ASA standard.
DATA COLLECTION
Assessment of Treatment Efficacy
apart. These questionnaires can be completed online via a link provided through REDCap in an email to the participant. At 14 days after administration of nitrous oxide, we expect the effects of nitrous oxide to wear off fully and patients' tinnitus should have returned to baseline. The baseline assessment for the second session will take place no sooner than 14 days after the first session, and therefore will assess whether this washout period of 14 days is accurate. The patient will not be allowed to participate in the second arm of the study until their Global Bother Scale score is within one category of their baseline score.
Assessment of Treatment Safety
Treatment safety will be assessed at several levels: adverse events (AE) related to (i) cardiovascular status; (ii) respiratory function; (iii) central nervous system; (iv) psychiatric symptoms,.
(i) Cardiovascular AEs, such as hyper-and hypotension, tachy-/bradycardia, will be identified by continuous hemodynamic monitoring during and after the treatment (ii) Respiratory AEs, such as respiratory depression and desaturation, will be identified by continuous pulsoximetry during and after treatment (iii) Central nervous system AEs will be assessed clinically.
(iv) Psychiatric AEs, will be assessed clinically.
DATA AND SAFETY MONITORING
The specific monitoring plan for this study is commensurate with the risks and the size and complexity of the investigations planned. The potential risks are attributable to the use of nitrous oxide. Based on these considerations the monitoring plan involves a DSMC including Dr. Peter Nagele, an attending anesthesiologist knowledgeable in nitrous oxide pharmacology, Dr. Jay Piccirillo, an attending otolaryngologist with experience with tinnitus patients, and Dr. Dorina Kallogjeri, a biostatistician with experience in conducting clinical trials. All reports of Serious Adverse Events or Unexpected Adverse Events will be investigated by the DSMC and reported to the WU HRPO/IRB per reporting guidelines.
Furthermore, the study principal investigator and study coordinator will monitor for breaches of confidentiality and other adverse events on an ongoing basis. Once the PI or study coordinator becomes aware of a reportable adverse event, the event will be reported to HRPO according to institutional guidelines.
DATA ANALYSIS
Standard descriptive statistics will describe the study population, responses to assessments, and severity of tinnitus. Data will be analyzed using SAS version 9.4 statistical software (SAS Institute, Inc. Cary, NC). Aim 1. To evaluate the effect of nitrous oxide as treatment of tinnitus.
The primary efficacy parameter will be the in the change in TFI. Secondary outcome measure will be the change in MAT. Baseline TFI and MAT will be defined as those determined immediately before a session. Post-treatment TFI and MAT will be compared to baseline TFI and MAT at each time point. A mixed model analysis using SAS Proc Mixed procedure will be used to explore the change in TFI score after treatment as compared to after placebo through exploration of the interaction effect of time*treatment. The mixed procedure allows for exploring information from measures nested within subjects nested within treatment groups. In addition, this analytical approach allows for investigation of the carry-over effect due to crossover design.
And finally, the number of subjects with 13 or more points difference in TFI (clinically important difference) [16] after each treatment arm will be identified and compared between active and placebo treatments using McNemars test.
RISK ASSESSMENT
Nitrous oxide. The side effects of nitrous oxide are well known to anesthesiologists. The dose (50%) and duration (40 minutes) used in this protocol are considered extremely safe and of low risk. Similar doses and durations are used in everyday dental practice without vital sign monitoring or supervision by a resuscitation-trained physician. With this dose of nitrous oxide, sedation may occur but not general anesthesia or respiratory depression. Previous evidence shows that the inactivating effect of nitrous oxide on vitamin B12 is dose and durationdependent and are minor when used as described in this protocol. An increase in plasma homocysteine by +25% and return to baseline within the next 24 hours is expected. Minor side effects after nitrous oxide exposure such as nausea and vomiting may occur which are typically self-limited and short. As a precaution against nausea, patients will be NPO for 2 hours prior to each intervention session, although liquids may be freely consumed. If a patient develops moderate to severe nausea and vomiting, we will administer 4mg of ondansetron.
Questionnaires. Participants may experience frustration and/or boredom completing the questionnaires. The participants may refuse to answer any questions for any reason.
